Amendment from Sen. Sanders was tabled in part to avoid adding a controversial provision that could slow the bill's passage, but may be debated during upcoming drug costs hearing.
Controversial drug importation legislation likely will not be attached to the FDA user fee reauthorization, but has gained support and may be considered during a congressional hearing to deal with drug costs.
It was the only issue debated during the May 11 Senate Health, Education, Labor and Pensions Committee mark-up of the...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
